Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06937177 · ClinicalTrials.gov registry record · Phase 2
Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy
A Phase 2 study of Cancer Weight Loss, sponsored by Endevica Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 17
- Study locations
NCT06937177 is a Phase 2 study of Cancer Weight Loss that is actively recruiting participants, run by Endevica Bio. The registered enrollment target is 120 participants. The trial reports 17 study locations across 11 states.
The verdict
NCT06937177, a Phase 2 study of Cancer Weight Loss, is actively recruiting participants, sponsored by Endevica Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 120 patients with newly diagnosed metastatic colorectal cancer. This study will evaluate different doses of B07 on weight, body composition and BMI in patients with sub-optimal BMIs (≤ 29 kg/m\^2). Treatment will start at the second cycle of first-line cancer chemotherapy and continue for 12-weeks with the goal of maintaining body weight and muscle mass in patients undergoing chemotherapy relative to control.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TCMCB07
Study Locations (17)
Florida
- Investigative Site - Hialeah
- Investigative Site - Margate
- Investigative Site - Miami Beach
- Investigative Site - Tamarac
California
- Investigative Site - Los Angeles
- Investigative Site - Los Angeles
Nebraska
- Investigative Site - Lincoln
- Investigative Site - Omaha
Texas
- Investigative Site - Kingwood
- Investigative Site - Laredo
Arizona
- Investigative Site - Tucson
Georgia
- Investigative Site - Atlanta
Kansas
- Investigative Site - Wichita
Michigan
- Investigative Site - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-04-28 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06937177
The ClinicalTrials.gov registry entry for NCT06937177 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endevica Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer Weight Loss appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06937177 reports 17 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Nebraska.
Frequently Asked Questions
What is clinical trial NCT06937177 about?
NCT06937177 is a clinical study titled "Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy". This is a randomized, double-blind, placebo-controlled study of B07, administered daily by subcutaneous (SC) injection, in up to 120 patients with newly diagnosed metastatic colorectal cancer. This study will evaluate different doses of B07 on weight, body composition and BMI in patients with sub-op...
What is the current status of trial NCT06937177?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-04-28. Estimated completion is 2026-09.
What conditions does trial NCT06937177 study?
This clinical trial studies the following conditions: Cancer Weight Loss.
What interventions are being tested in trial NCT06937177?
The interventions under investigation include: Placebo (DRUG), TCMCB07 (DRUG).
Who is sponsoring clinical trial NCT06937177?
This trial is sponsored by Endevica Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06937177 being conducted?
This trial has 17 study locations across Arizona, California, Florida, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.